文献速递胃肠动力与功能性疾病

AGA临床实践更新:功能性烧心的专家综述

AGA Clinical Practice Update on Functional Heartburn: Expert Review.
PubMed 文献 · Gastroenterology · 2020-02-01

美国胃肠病学会(AGA)发布功能性烧心临床实践更新,基于专家综述提出7条最佳实践建议。诊断需在最大剂量PPI治疗3个月后仍有症状,并排除解剖、黏膜及动力异常,且pH监测证实酸暴露生理性且无 reflux-symptom 关联。PPI对功能性烧心无治疗价值,神经调节剂、针灸和催眠疗法可能获益,抗反流手术和内镜治疗不推荐。

要点

  • 功能性烧心诊断需最大剂量PPI治疗3个月后仍有症状,并排除黏膜及动力异常。
  • 诊断需pH监测(或pH-阻抗监测)证实生理性酸暴露且无 reflux-symptom 关联。
  • PPI对功能性烧心无治疗价值,神经调节剂可能作为主要或附加治疗获益。

核心结论

  • 功能性烧心是在最大剂量PPI治疗3个月后仍持续存在胸骨后烧灼痛或不适,且排除解剖、黏膜及动力异常并证实生理性酸暴露且无 reflux-symptom 关联的疾病。
  • PPI对功能性烧心无治疗价值,但神经调节剂、针灸和催眠疗法可能获益,抗反流手术和内镜治疗不推荐。

研究设计与样本

  • 美国胃肠病学会(AGA)发布的专家综述,提出7条最佳实践建议。

主要发现

  • 功能性烧心与已证实GERD重叠的诊断依据Rome IV标准,需在最大PPI治疗下pH-阻抗监测显示生理性酸暴露且无 reflux-symptom 关联。
  • 神经调节剂包括三环类抗抑郁药、选择性5-羟色胺再摄取抑制剂、替加色罗和组胺-2受体拮抗剂,可作为功能性烧心的主要治疗或重叠GERD的附加治疗。
  • 针灸和催眠疗法可能作为功能性烧心的单一治疗或联合其他治疗模式的辅助治疗。

关键数值与推荐

  • 功能性烧心诊断需在最大(双倍剂量)PPI治疗、餐前适当服用3个月期间,胸骨后烧灼痛或不适持续存在。
  • 诊断需上消化道内镜及食管活检排除解剖和黏膜异常,食管高分辨率测压排除主要动力障碍,以及停用PPI的pH监测(或已证实GERD患者治疗中pH-阻抗监测)证实远端食管生理性酸暴露且无 reflux-symptom 关联(即症状指数和症状关联概率阴性)。
  • 功能性烧心与已证实GERD重叠的诊断依据Rome IV标准:有已证实GERD病史(pH研究阳性、糜烂性食管炎、Barrett食管或食管溃疡),最大PPI治疗下烧心持续,且治疗中pH-阻抗监测显示生理性酸暴露且无 reflux-symptom 关联。
  • PPI对功能性烧心无治疗价值,例外为已证实GERD与功能性烧心重叠。
  • 抗反流手术和内镜GERD治疗模式对功能性烧心无治疗获益,不应推荐。

临床怎么用

  • 对最大剂量PPI治疗3个月仍持续烧心症状的患者,应考虑功能性烧心诊断并完善内镜、测压及pH监测。
  • 确诊功能性烧心后,PPI无治疗价值,可考虑神经调节剂、针灸或催眠疗法作为治疗选择。
  • 对已证实GERD与功能性烧心重叠的患者,可继续PPI治疗并考虑神经调节剂作为附加治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BEST PRACTICE ADVICE 1: A diagnosis of functional heartburn should be considered when retrosternal burning pain or discomfort persists despite maximal (double-dose) proton pump inhibitor (PPI) therapy taken appropriately before meals during a 3-month period. BEST PRACTICE ADVICE 2: A diagnosis of functional heartburn requires upper endoscopy with esophageal biopsies to rule out anatomic and mucosal abnormalities, esophageal high-resolution manometry to rule out major motor disorders, and pH monitoring off PPI therapy (or pH-impedance monitoring on therapy in patients with proven gastroesophageal reflux disease [GERD]), to document physiologic levels of esophageal acid exposure in the distal esophagus with absence of reflux-symptom association (ie, negative symptom index and symptom association probability). BEST PRACTICE ADVICE 3: Overlap of functional heartburn with proven GERD is diagnosed according to Rome IV criteria when heartburn persists despite maximal PPI therapy in patients with history of proven GERD (ie, positive pH study, erosive esophagitis, Barrett's esophagus, or esophageal ulcer), and pH impedance testing on PPI therapy demonstrates physiologic acid exposure without reflux-symptom association (ie, negative symptom index and symptom association probability). BEST PRACTICE ADVICE 4: PPIs have no therapeutic value in functional heartburn, the exception being proven GERD that overlaps with functional heartburn. BEST PRACTICE ADVICE 5: Neuromodulators, including tricyclic antidepressants, selective serotonin reuptake inhibitors, tegaserod, and histamine-2 receptor antagonists have benefit as either primary therapy in functional heartburn or as add-on therapy in functional heartburn that overlaps with proven GERD. BEST PRACTICE ADVICE 6: Based on available evidence, acupuncture and hypnotherapy may have benefit as monotherapy in functional heartburn, or as adjunctive therapy combined with other therapeutic modalities. BEST PRACTICE ADVICE 7: Based on available evidence, anti-reflux surgery and endoscopic GERD treatment modalities have no therapeutic benefit in functional heartburn and should not be recommended.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Fass R, Zerbib F, Gyawali CP, et al. AGA Clinical Practice Update on Functional Heartburn: Expert Review. Gastroenterology. 2020. PMID: 32017911. doi:10.1053/j.gastro.2020.01.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。